Drug Trial Radar · NCT06649747
Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain
Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
408
Planned (sponsor's estimate)
Start
Apr 1, 2027
Primary completion
Mar 31, 2032
Study completion Mar 31, 2032
Sponsor
- Lead sponsor
- Afasci IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate if the drug candidate AFA-281 works to treat chronic low back and leg pain caused by painful lumbosacral radiculopathy (PLSR) in adults. This trial will also evaluate the safety of AFA-281. The main questions it aims to answer are: * Does AFA-281 mitigate pain? * What are the side effects (if any)? Researchers will compare AFA-281 to a placebo (a look-alike substance that contains no drug) to see if AFA-281 works to treat chronic low back and leg pain. Participants will: * Take drug AFA-281 or a placebo three times every day for 4 weeks * Visit the clinic once every 2 weeks for checkups and tests * Keep a diary of their pain scores and about mood and sleep questionnaires, and the number of times they use a rescue pain medicines.
Conditions
- Lumbosacral Radiculopathy
Interventions
AFA-281Drug
A small molecule, orally available
Primary outcomes
What the sponsor says the trial is designed to measure.
- Numeric Pain Rating ScaleTime frame: 2 weeks baseline and 4 weeks of treatment, and 2 weeks after the end of treatment
- Safety- Number of Participants with Treatment-Related Adverse Events (AEs)Time frame: Baseline (2 weeks) and 4 weeks of the treatment, and 4 weeks of followup
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.